Hepatitis C Virus Infection
Conditions
Keywords
Sustained Virologic Response, Direct Acting Antiviral, Combination Therapy, Liver Diseases, Digestive System Diseases, Hepatitis, Viral, Human, Enterovirus Infections, Picornaviridae Infections, RNA Virus Infections, Flaviviridae Infections, Antiviral Agents, Anti-Infective Agents, Therapeutic Uses, Pharmacologic Actions, Antimetabolites, Molecular Mechanisms of Pharmacological Action
Brief summary
The primary objective of the study is to evaluate the safety and tolerability of voxilaprevir (formerly GS-9857) alone or with sofosbuvir (SOF)/velpatasvir (VEL) fixed dose combination (FDC) and antiviral activity of voxilaprevir in adults with genotype 1, 2, 3, 4 hepatitis C virus (HCV) infection. All participants will be monitored for up to 48 weeks after the last dose.
Interventions
DRUGVoxilaprevir
Voxilaprevir tablets administered orally once daily
DRUGPlacebo to match voxilaprevir
Placebo to match voxilaprevir tablets administered orally once daily
DRUGSOF/VEL
400 mg/100 mg FDC tablet administered orally once daily
Sponsors
Gilead Sciences
Study design
Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
DOUBLE (Subject, Investigator)
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
Key Inclusion Criteria: * Chronic genotype 1-4 HCV infection * For Cohorts 1-9, HCV RNA ≥ 100,000 IU/mL at screening (no HCV RNA restriction for Cohort 10) * Screening laboratory values within defined thresholds * Use of two effective contraception methods if female of childbearing potential or sexually active male Key
Exclusion criteria
* Pregnant or nursing female or male with pregnant female partner * Presence of cirrhosis * Prior exposure to approved or experimental HCV Protease Inhibitors * Co-infection with HIV or hepatitis B virus (HBV) * Current or prior history of clinical hepatic decompensation * Chronic use of systemic immunosuppressive agents * History of clinically significant illness or any other medical disorder that may interfere with participant's treatment, assessment or compliance with the protocol Note: Other protocol defined Inclusion/
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Percentage of Participants Experiencing Treatment Emergent Adverse Events | First dose date up to Day 3 plus 30 days | — |
| Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | First dose date up to Day 3 plus 30 days | Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The severity of laboratory abnormalities was assessed as Grade 0, 1 (mild), 2 (moderate), 3 (severe), or 4 (potentially life threatening) using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The most severe graded abnormality from all tests was counted for each participant. |
| Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Baseline; Days 4, 5, 6, 7, 8, 10, and Week 48 | The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6). Data are summarized by treatment/cohort and placebo. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Baseline (Pre Day 1 Dose); Days 4, 5, 6, 7, 8, 10, and Week 48 | The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6). |
| Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Baseline; Days 4, 5, 6, 7, 8, 10, and Week 48 | Categorical declines from baseline were summarized by the number of participants with a \< 1, ≥ 1 to \<2, ≥ 2 to \<3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline to each postdose assessment up to Week 48 by treatment/cohort and placebo. The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6). |
| Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Days 4, 5, 6, 7, 8, 10, and Week 48 | The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 15 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay. The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6). |
Countries
Puerto Rico, United States
Participant flow
Recruitment details
Participants were enrolled at study sites in United States and Puerto Rico. The first participant was screened on 13 June 2014. The last study visit occurred on 28 September 2015.
Pre-assignment details
Participants were enrolled in Cohorts 1, 2, 3, 4, 5, 6 and 10. Cohorts 7, 8, and 9 were not conducted.
Participants by arm
| Arm | Count |
|---|---|
| Placebo Participants with HCV infection received placebo once daily for 3 days under fasted conditions. This arm was part of cohorts 1, 2 and 3. | 8 |
| Voxilaprevir 50 mg Participants with HCV infection received voxilaprevir 50 mg once daily for 3 days under fasted conditions. This arm was part of cohorts 1 and 2. | 14 |
| Voxilaprevir 100 mg Participants with HCV infection received voxilaprevir 100 mg once daily for 3 days under fasted conditions. This arm was part of cohorts 1, 2, 3, 4, 5 and 6. | 30 |
| Voxilaprevir 300 mg Participants with HCV infection received voxilaprevir 300 mg once daily for 3 days under fasted conditions. This arm was part of cohorts 1 and 2. | 15 |
| Voxilaprevir 100 mg Fed Participants with HCV infection received voxilaprevir 100 mg once daily for 3 days under fed conditions. This arm was part of cohorts 1, 2, 3, 4, 5 and 6. | 6 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg Participants with HCV infection received voxilaprevir 100 mg on Day 1 and voxilaprevir 100 mg plus SOF/VEL (400/100 mg) FDC on Days 2 and 3 after moderate fat meal. This arm was part of cohort 10. | 16 |
| Total | 89 |
Withdrawals & dropouts
| Period | Reason | FG000 | FG001 | FG002 | FG003 | FG004 | FG005 |
|---|---|---|---|---|---|---|---|
| Overall Study | Enrolled but Never Dosed | 1 | 6 | 3 | 1 | 1 | 0 |
| Overall Study | Investigator's Discretion | 1 | 0 | 1 | 2 | 2 | 15 |
| Overall Study | Lost to Follow-up | 1 | 2 | 2 | 3 | 0 | 1 |
| Overall Study | Withdrew Consent | 2 | 5 | 10 | 2 | 0 | 0 |
Baseline characteristics
| Characteristic | Placebo | Voxilaprevir 50 mg | Voxilaprevir 100 mg | Voxilaprevir 300 mg | Voxilaprevir 100 mg Fed | Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Total |
|---|---|---|---|---|---|---|---|
| Age, Continuous | 52 years STANDARD_DEVIATION 6.1 | 49 years STANDARD_DEVIATION 7.7 | 52 years STANDARD_DEVIATION 8 | 43 years STANDARD_DEVIATION 9.4 | 51 years STANDARD_DEVIATION 6.2 | 56 years STANDARD_DEVIATION 5.2 | 51 years STANDARD_DEVIATION 8.4 |
| HCV Genotype 1a | 4 Participants | 8 Participants | 8 Participants | 8 Participants | 0 Participants | 9 Participants | 37 Participants |
| HCV Genotype 1b | 0 Participants | 0 Participants | 6 Participants | 0 Participants | 0 Participants | 3 Participants | 9 Participants |
| HCV Genotype 2 | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 0 Participants | 1 Participants | 1 Participants |
| HCV Genotype 2a/2c | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| HCV Genotype 2b | 2 Participants | 0 Participants | 4 Participants | 0 Participants | 0 Participants | 2 Participants | 8 Participants |
| HCV Genotype 3a | 2 Participants | 6 Participants | 6 Participants | 7 Participants | 6 Participants | 1 Participants | 28 Participants |
| HCV Genotype 4 | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| HCV Genotype 4a/4c/4d | 0 Participants | 0 Participants | 2 Participants | 0 Participants | 0 Participants | 0 Participants | 2 Participants |
| HCV RNA | 6.6 log10 IU/mL STANDARD_DEVIATION 0.39 | 6.0 log10 IU/mL STANDARD_DEVIATION 0.64 | 6.4 log10 IU/mL STANDARD_DEVIATION 0.53 | 6.0 log10 IU/mL STANDARD_DEVIATION 0.64 | 6.0 log10 IU/mL STANDARD_DEVIATION 0.87 | 6.2 log10 IU/mL STANDARD_DEVIATION 0.83 | 6.2 log10 IU/mL STANDARD_DEVIATION 0.65 |
| HCV RNA Category < 800,000 IU/mL | 1 Participants | 7 Participants | 6 Participants | 6 Participants | 4 Participants | 4 Participants | 28 Participants |
| HCV RNA Category ≥ 800,000 IU/mL | 7 Participants | 7 Participants | 24 Participants | 9 Participants | 2 Participants | 12 Participants | 61 Participants |
| Race/Ethnicity, Customized Black or African American | 2 Participants | 4 Participants | 12 Participants | 3 Participants | 1 Participants | 0 Participants | 22 Participants |
| Race/Ethnicity, Customized Hispanic or Latino | 2 Participants | 7 Participants | 12 Participants | 8 Participants | 6 Participants | 9 Participants | 44 Participants |
| Race/Ethnicity, Customized Not Hispanic or Latino | 6 Participants | 7 Participants | 18 Participants | 7 Participants | 0 Participants | 7 Participants | 45 Participants |
| Race/Ethnicity, Customized White | 6 Participants | 10 Participants | 18 Participants | 12 Participants | 5 Participants | 16 Participants | 67 Participants |
| Sex: Female, Male Female | 1 Participants | 5 Participants | 9 Participants | 5 Participants | 2 Participants | 7 Participants | 29 Participants |
| Sex: Female, Male Male | 7 Participants | 9 Participants | 21 Participants | 10 Participants | 4 Participants | 9 Participants | 60 Participants |
Adverse events
| Event type | EG000 affected / at risk | EG001 affected / at risk | EG002 affected / at risk | EG003 affected / at risk | EG004 affected / at risk | EG005 affected / at risk |
|---|---|---|---|---|---|---|
| deaths Total, all-cause mortality | 0 / 8 | 0 / 14 | 0 / 30 | 0 / 15 | 0 / 6 | 0 / 16 |
| other Total, other adverse events | 2 / 8 | 2 / 14 | 2 / 30 | 2 / 15 | 1 / 6 | 2 / 16 |
| serious Total, serious adverse events | 0 / 8 | 0 / 14 | 0 / 30 | 0 / 15 | 1 / 6 | 0 / 16 |
Outcome results
Primary
Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA
The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6). Data are summarized by treatment/cohort and placebo.
Time frame: Baseline; Days 4, 5, 6, 7, 8, 10, and Week 48
Population: The Efficacy Analysis Set included all enrolled participants with appropriate genotype who received at least one dose of the study drug (voxilaprevir or placebo) and with at least one on-treatment HCV RNA assessment. Participants in the Efficacy Analysis Set with available data were analyzed.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -0.21 log10 IU/mL | Standard Deviation 0.479 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -0.20 log10 IU/mL | Standard Deviation 0.519 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -0.12 log10 IU/mL | Standard Deviation 0.136 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | 0.01 log10 IU/mL | Standard Deviation 0.34 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | 0.13 log10 IU/mL | Standard Deviation 0.26 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.41 log10 IU/mL | Standard Deviation 0.873 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -0.06 log10 IU/mL | Standard Deviation 0.091 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -2.69 log10 IU/mL | Standard Deviation 1.116 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.81 log10 IU/mL | Standard Deviation 0.516 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.58 log10 IU/mL | Standard Deviation 1.104 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.45 log10 IU/mL | Standard Deviation 0.829 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.08 log10 IU/mL | Standard Deviation 0.337 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -2.92 log10 IU/mL | Standard Deviation 1.069 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -3.15 log10 IU/mL | Standard Deviation 0.973 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -3.54 log10 IU/mL | Standard Deviation 0.663 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.78 log10 IU/mL | Standard Deviation 0.71 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.97 log10 IU/mL | Standard Deviation 0.608 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | -0.80 log10 IU/mL | Standard Deviation 2.094 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -4.03 log10 IU/mL | Standard Deviation 0.594 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -3.33 log10 IU/mL | Standard Deviation 0.756 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -3.88 log10 IU/mL | Standard Deviation 0.729 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | -0.73 log10 IU/mL | Standard Deviation 2.352 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.33 log10 IU/mL | Standard Deviation 0.902 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -3.48 log10 IU/mL | Standard Deviation 0.695 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.47 log10 IU/mL | Standard Deviation 0.763 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -2.97 log10 IU/mL | Standard Deviation 0.918 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.37 log10 IU/mL | Standard Deviation 0.894 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -3.23 log10 IU/mL | Standard Deviation 0.726 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | 0.02 log10 IU/mL | Standard Deviation 0.089 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -0.24 log10 IU/mL | Standard Deviation 0.813 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -0.17 log10 IU/mL | Standard Deviation 0.285 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -0.06 log10 IU/mL | Standard Deviation 0.051 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -0.14 log10 IU/mL | Standard Deviation 0.158 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -0.23 log10 IU/mL | Standard Deviation 0.18 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.41 log10 IU/mL | — |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -1.06 log10 IU/mL | Standard Deviation 0.632 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | -0.03 log10 IU/mL | Standard Deviation 0.221 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -0.28 log10 IU/mL | Standard Deviation 0.33 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -1.43 log10 IU/mL | Standard Deviation 0.606 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -1.47 log10 IU/mL | Standard Deviation 0.416 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -0.53 log10 IU/mL | Standard Deviation 0.379 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -0.76 log10 IU/mL | Standard Deviation 0.352 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -1.79 log10 IU/mL | Standard Deviation 0.627 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.54 log10 IU/mL | — |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.20 log10 IU/mL | Standard Deviation 0.364 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -1.18 log10 IU/mL | Standard Deviation 1.055 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -2.52 log10 IU/mL | Standard Deviation 0.739 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.00 log10 IU/mL | Standard Deviation 0.47 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -2.00 log10 IU/mL | Standard Deviation 0.378 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.28 log10 IU/mL | Standard Deviation 0.515 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.06 log10 IU/mL | Standard Deviation 0.37 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -2.74 log10 IU/mL | Standard Deviation 0.916 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -2.89 log10 IU/mL | Standard Deviation 0.763 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.13 log10 IU/mL | Standard Deviation 0.736 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.57 log10 IU/mL | Standard Deviation 0.483 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -2.17 log10 IU/mL | Standard Deviation 1.394 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -0.05 log10 IU/mL | Standard Deviation 0.058 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -0.04 log10 IU/mL | Standard Deviation 0.139 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -0.12 log10 IU/mL | Standard Deviation 0.151 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -0.05 log10 IU/mL | Standard Deviation 0.09 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -0.13 log10 IU/mL | Standard Deviation 0.022 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | 0.00 log10 IU/mL | Standard Deviation 0.104 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | -0.02 log10 IU/mL | — |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.41 log10 IU/mL | Standard Deviation 0.444 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.22 log10 IU/mL | Standard Deviation 0.689 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -2.48 log10 IU/mL | Standard Deviation 0.355 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | -0.02 log10 IU/mL | — |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -2.28 log10 IU/mL | Standard Deviation 0.469 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -2.80 log10 IU/mL | Standard Deviation 0.494 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.37 log10 IU/mL | Standard Deviation 0.48 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.50 log10 IU/mL | Standard Deviation 0.677 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -3.70 log10 IU/mL | Standard Deviation 0.877 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.61 log10 IU/mL | Standard Deviation 0.702 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -3.61 log10 IU/mL | Standard Deviation 0.674 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -3.53 log10 IU/mL | Standard Deviation 0.637 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.69 log10 IU/mL | Standard Deviation 0.879 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.18 log10 IU/mL | Standard Deviation 0.247 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.57 log10 IU/mL | Standard Deviation 0.227 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -3.42 log10 IU/mL | Standard Deviation 0.71 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -3.61 log10 IU/mL | Standard Deviation 0.601 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -3.60 log10 IU/mL | Standard Deviation 0.39 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | -0.57 log10 IU/mL | Standard Deviation 2.389 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -3.27 log10 IU/mL | Standard Deviation 0.627 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -3.08 log10 IU/mL | Standard Deviation 0.74 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 5 | -2.45 log10 IU/mL | Standard Deviation 0.664 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 8 | -1.43 log10 IU/mL | Standard Deviation 0.987 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 7 | -1.74 log10 IU/mL | Standard Deviation 0.885 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 10 | -0.62 log10 IU/mL | Standard Deviation 1.085 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Week 48 | 0.16 log10 IU/mL | Standard Deviation 0.044 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 6 | -2.04 log10 IU/mL | Standard Deviation 0.706 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Change From Baseline in Plasma HCV RNA | Change at Day 4 | -3.06 log10 IU/mL | Standard Deviation 0.752 |
Primary
Percentage of Participants Experiencing Treatment Emergent Adverse Events
Time frame: First dose date up to Day 3 plus 30 days
Population: The Safety Analysis Set included participants who were randomized and received at least 1 dose of study drug (voxilaprevir or placebo). Data were summarized by dose.
| Arm | Measure | Value (NUMBER) |
|---|---|---|
| Placebo | Percentage of Participants Experiencing Treatment Emergent Adverse Events | 25.0 percentage of participants |
| Voxilaprevir 50 mg | Percentage of Participants Experiencing Treatment Emergent Adverse Events | 14.3 percentage of participants |
| Voxilaprevir 100 mg | Percentage of Participants Experiencing Treatment Emergent Adverse Events | 16.7 percentage of participants |
| Voxilaprevir 300 mg | Percentage of Participants Experiencing Treatment Emergent Adverse Events | 13.3 percentage of participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Experiencing Treatment Emergent Adverse Events | 33.3 percentage of participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Experiencing Treatment Emergent Adverse Events | 12.5 percentage of participants |
Primary
Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities
Treatment-emergent laboratory abnormalities were defined as values that increase at least one toxicity grade from baseline. The severity of laboratory abnormalities was assessed as Grade 0, 1 (mild), 2 (moderate), 3 (severe), or 4 (potentially life threatening) using the Common Terminology Criteria for Adverse Events (CTCAE), version 4.03. The most severe graded abnormality from all tests was counted for each participant.
Time frame: First dose date up to Day 3 plus 30 days
Population: Participants in the Safety Analysis Set were analyzed. Data were summarized by dose.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 1 | 37.5 percentage of participants |
| Placebo | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 2 | 25.0 percentage of participants |
| Placebo | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 3 | 0 percentage of participants |
| Placebo | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 4 | 0 percentage of participants |
| Voxilaprevir 50 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 3 | 14.3 percentage of participants |
| Voxilaprevir 50 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 2 | 28.6 percentage of participants |
| Voxilaprevir 50 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 1 | 28.6 percentage of participants |
| Voxilaprevir 50 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 4 | 0 percentage of participants |
| Voxilaprevir 100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 4 | 3.3 percentage of participants |
| Voxilaprevir 100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 3 | 10.0 percentage of participants |
| Voxilaprevir 100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 2 | 33.3 percentage of participants |
| Voxilaprevir 100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 1 | 26.7 percentage of participants |
| Voxilaprevir 300 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 1 | 20.0 percentage of participants |
| Voxilaprevir 300 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 4 | 0 percentage of participants |
| Voxilaprevir 300 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 2 | 13.3 percentage of participants |
| Voxilaprevir 300 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 3 | 26.7 percentage of participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 3 | 33.3 percentage of participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 4 | 0 percentage of participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 2 | 0 percentage of participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 1 | 50.0 percentage of participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 2 | 12.5 percentage of participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 3 | 0 percentage of participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 4 | 0 percentage of participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Experiencing Treatment-Emergent Laboratory Abnormalities | Grade 1 | 62.5 percentage of participants |
Secondary
Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48
The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6).
Time frame: Baseline (Pre Day 1 Dose); Days 4, 5, 6, 7, 8, 10, and Week 48
Population: Participants in the Efficacy Analysis Set with available data were analyzed. Data are summarized by treatment/cohort and placebo.
| Arm | Measure | Group | Value (MEAN) | Dispersion |
|---|---|---|---|---|
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 6.53 log10 IU/mL | Standard Deviation 0.426 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 6.62 log10 IU/mL | Standard Deviation 0.378 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 6.52 log10 IU/mL | Standard Deviation 0.32 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.73 log10 IU/mL | Standard Deviation 0.307 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 6.74 log10 IU/mL | Standard Deviation 0.059 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 6.68 log10 IU/mL | Standard Deviation 0.263 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 6.86 log10 IU/mL | Standard Deviation 0.144 |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.97 log10 IU/mL | Standard Deviation 0.488 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.30 log10 IU/mL | Standard Deviation 0.497 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 2.85 log10 IU/mL | Standard Deviation 1 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.56 log10 IU/mL | Standard Deviation 0.705 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.29 log10 IU/mL | Standard Deviation 0.825 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 3.15 log10 IU/mL | Standard Deviation 1.268 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.73 log10 IU/mL | Standard Deviation 1.203 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 3.61 log10 IU/mL | Standard Deviation 1.041 |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 3.38 log10 IU/mL | Standard Deviation 1.019 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 2.81 log10 IU/mL | Standard Deviation 0.901 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 2.47 log10 IU/mL | Standard Deviation 0.821 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 5.55 log10 IU/mL | Standard Deviation 2.007 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 2.57 log10 IU/mL | Standard Deviation 1.028 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.35 log10 IU/mL | Standard Deviation 0.526 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.33 log10 IU/mL | Standard Deviation 0.643 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 3.03 log10 IU/mL | Standard Deviation 0.857 |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.38 log10 IU/mL | Standard Deviation 0.759 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 2.57 log10 IU/mL | Standard Deviation 0.818 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 3.07 log10 IU/mL | Standard Deviation 0.887 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 2.81 log10 IU/mL | Standard Deviation 0.671 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.05 log10 IU/mL | Standard Deviation 0.558 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 2.56 log10 IU/mL | Standard Deviation 0.714 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.72 log10 IU/mL | Standard Deviation 0.943 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 5.20 log10 IU/mL | Standard Deviation 2.085 |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.67 log10 IU/mL | Standard Deviation 0.947 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 6.13 log10 IU/mL | Standard Deviation 0.569 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 5.88 log10 IU/mL | Standard Deviation 0.3 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.11 log10 IU/mL | Standard Deviation 0.48 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 5.87 log10 IU/mL | Standard Deviation 0.332 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 5.94 log10 IU/mL | Standard Deviation 0.195 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.18 log10 IU/mL | — |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 6.05 log10 IU/mL | Standard Deviation 0.532 |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 5.97 log10 IU/mL | Standard Deviation 0.323 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 4.55 log10 IU/mL | Standard Deviation 1.203 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 4.19 log10 IU/mL | Standard Deviation 1.104 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 5.08 log10 IU/mL | Standard Deviation 0.655 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 5.61 log10 IU/mL | Standard Deviation 0.612 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 5.13 log10 IU/mL | Standard Deviation 0.207 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 4.85 log10 IU/mL | Standard Deviation 0.886 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 5.43 log10 IU/mL | Standard Deviation 0.803 |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 4.22 log10 IU/mL | Standard Deviation 0.878 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 3.75 log10 IU/mL | Standard Deviation 0.455 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 4.23 log10 IU/mL | Standard Deviation 0.604 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 3.54 log10 IU/mL | Standard Deviation 0.455 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 4.75 log10 IU/mL | Standard Deviation 0.268 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.75 log10 IU/mL | Standard Deviation 0.346 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 5.56 log10 IU/mL | Standard Deviation 0.987 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 4.96 log10 IU/mL | Standard Deviation 0.531 |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 7.29 log10 IU/mL | — |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.44 log10 IU/mL | Standard Deviation 0.693 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.38 log10 IU/mL | Standard Deviation 1.479 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 3.27 log10 IU/mL | Standard Deviation 1.1 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 3.12 log10 IU/mL | Standard Deviation 0.991 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.01 log10 IU/mL | Standard Deviation 0.773 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.73 log10 IU/mL | Standard Deviation 0.78 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 3.83 log10 IU/mL | Standard Deviation 1.417 |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 2.88 log10 IU/mL | Standard Deviation 0.882 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 6.67 log10 IU/mL | Standard Deviation 0.001 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.71 log10 IU/mL | Standard Deviation 0.059 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 6.58 log10 IU/mL | Standard Deviation 0.081 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 6.71 log10 IU/mL | Standard Deviation 0.164 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 6.59 log10 IU/mL | Standard Deviation 0.21 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 6.66 log10 IU/mL | Standard Deviation 0.031 |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.65 log10 IU/mL | — |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 6.68 log10 IU/mL | Standard Deviation 0.199 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 3.44 log10 IU/mL | Standard Deviation 0.613 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.13 log10 IU/mL | — |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.24 log10 IU/mL | Standard Deviation 0.394 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 3.96 log10 IU/mL | Standard Deviation 0.555 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 3.02 log10 IU/mL | Standard Deviation 0.754 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.83 log10 IU/mL | Standard Deviation 0.611 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.87 log10 IU/mL | Standard Deviation 0.603 |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 3.76 log10 IU/mL | Standard Deviation 0.497 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 2.45 log10 IU/mL | Standard Deviation 0.359 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.16 log10 IU/mL | Standard Deviation 0.73 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.65 log10 IU/mL | Standard Deviation 0.533 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.55 log10 IU/mL | Standard Deviation 0.549 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 2.46 log10 IU/mL | Standard Deviation 0.3 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 2.62 log10 IU/mL | Standard Deviation 0.278 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 2.54 log10 IU/mL | Standard Deviation 0.553 |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 6.34 log10 IU/mL | Standard Deviation 0.696 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 2.96 log10 IU/mL | Standard Deviation 1.111 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 3.15 log10 IU/mL | Standard Deviation 1.21 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 2.82 log10 IU/mL | Standard Deviation 1.111 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 2.85 log10 IU/mL | Standard Deviation 0.685 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 2.63 log10 IU/mL | Standard Deviation 0.764 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.67 log10 IU/mL | Standard Deviation 0.5 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.23 log10 IU/mL | Standard Deviation 0.608 |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 5.65 log10 IU/mL | Standard Deviation 2.473 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 8 | 4.59 log10 IU/mL | Standard Deviation 0.528 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 4 | 2.95 log10 IU/mL | Standard Deviation 0.505 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 10 | 5.40 log10 IU/mL | Standard Deviation 0.697 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 7 | 4.27 log10 IU/mL | Standard Deviation 0.485 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Week 48 | 5.98 log10 IU/mL | Standard Deviation 0.891 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 6 | 3.98 log10 IU/mL | Standard Deviation 0.413 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Pre Day 1 Dose | 6.01 log10 IU/mL | Standard Deviation 0.866 |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Absolute HCV RNA Level Through Week 48 | Day 5 | 3.56 log10 IU/mL | Standard Deviation 0.273 |
Secondary
Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA
Categorical declines from baseline were summarized by the number of participants with a \< 1, ≥ 1 to \<2, ≥ 2 to \<3, or ≥ 3 log10 IU/mL decrease in HCV RNA from baseline to each postdose assessment up to Week 48 by treatment/cohort and placebo. The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6).
Time frame: Baseline; Days 4, 5, 6, 7, 8, 10, and Week 48
Population: Participants in the Efficacy Analysis Set were analyzed.
| Arm | Measure | Group | Category | Value (COUNT_OF_PARTICIPANTS) |
|---|---|---|---|---|
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 2 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 4 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 50 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 8 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 7 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 5 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 2 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 5 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 3 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 5 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 5 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 5 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 5 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 1 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Placebo (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 5 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 5 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 6 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 1 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥3 log10 IU/mL decrease in HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Week 48 | Missing HCV RNA | 2 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | ≥3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 5 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | < 1 log10 IU/mL decrease in HCV RNA | 4 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 10 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | < 1 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | < 1 log10 IU/mL decrease in HCV RNA | 3 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥3 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 8 | ≥2 and <3 log10 IU/mL decrease in HCV RNA | 1 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 6 | Missing HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 4 | < 1 log10 IU/mL decrease in HCV RNA | 0 Participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Antiviral Activity of Voxilaprevir as Measured by Number of Participants Achieving Reductions From Baseline in HCV RNA | Day 7 | ≥1 and <2 log10 IU/mL decrease in HCV RNA | 2 Participants |
Secondary
Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND)
The lower limit of quantitation (LLOQ) detection for HCV RNA levels was 15 IU/mL. HCV detected means calculated HCV RNA level is below LLOQ of the assay. The outcome measure was assessed to evaluate antiviral activity of voxilaprevir only (cohorts 1 through 6).
Time frame: Days 4, 5, 6, 7, 8, 10, and Week 48
Population: Participants in the Efficacy Analysis Set were analyzed. Data are summarized by treatment/cohort and placebo.
| Arm | Measure | Group | Value (NUMBER) |
|---|---|---|---|
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Placebo | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 50 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 1 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 1 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 1 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 1 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 1 participants |
| Voxilaprevir 300 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 1 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg + SOF/VEL 400/100 mg | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 300 mg (GT 3, Cohort 2) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 1 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Placebo (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 2, Cohort 3) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 4, Cohort 4) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 1 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 1 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 1 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg (GT 1b, Cohort 5) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 5 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 8 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 6 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 10 < LLOQ TND | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 4 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Day 7 < LLOQ detected | 0 participants |
| Voxilaprevir 100 mg Fed (GT 3a, Cohort 6) | Percentage of Participants Who Have HCV RNA < Lower Limit of Quantitation (LLOQ) Detected, and < LLOQ Target Not Detected (TND) | Week 48 < LLOQ TND | 0 participants |